HEALTHWAY MEDICAL CORPORATION LIMITED

(Company Registration No.: 200708625C) (Incorporated in the Republic of Singapore)

RESPONSES TO QUESTIONS RECEIVED FROM SHAREHOLDERS FOR ANNUAL GENERAL MEETING FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2020

The board of directors ("**Board**" or "**Directors**") of Healthway Medical Corporation Limited ("**Company**", and together with its subsidiaries, "**Group**") refers to the publishing of its annual report and related documents on the SGXNET on 8 April 2021. The Company has received three (3) questions from the Shareholders by the cut-off date/ time of 16 April 2021 (Friday) at 5:00 p.m. which substantively relate to the following, and to which the Company wishes to provide its responses:-

Question 1

(i) Please advise how many vaccination centre and mobile vaccination team the Group had been contracted to operate as part of the nationwide vaccination programme?

Response: The Group currently operates four (4) vaccination centres and one (1) mobile vaccination team as a part of the nationwide vaccination programme.

What is the contract value and tenure for each vaccination centre and mobile vaccination team?

Response: The details of the contract sum of the vaccination projects awarded to the Group is available publicly through the Singapore Government's e-procurement portal at GeBIZ:https://www.gebiz.gov.sg.

(ii) With this vaccination contracts, how is the Group coping with the operations of its 89 clinics and medical centres?

Response: With contract staff and additional hiring, the Group has sufficient resources, including the doctors and medical professionals to operate all its clinics, medical centres and the Vaccination centres.

Question 2

Re the 22 Oct 2020 announcement on Teleconsultation App, please provide update regarding:

- (i) the level of integration of specialists in the App;
- (ii) traction or take-up rate of this services especially now that we are well into Phase 3;
- (iii) % contribution to revenue

Response: The Group currently offers teleconsultation services across all its GP and Specialist clinics. With the launch of Teleconsultation App, the Group has embarked on omni-channel approach to better manage healthcare concerns of individual patients. The contribution of teleconsultation services to the Group revenue is minimal for now, however, with a gradual shift in healthcare landscape from a traditional acute care system to one of preventive care, the Group expect that teleconsultation services shall continue to gain traction even after the implementation of phase-3 of Circuit Breaker.

Question 3

Re the 29 March 2021 announcement, post vesting of 2nd tranche of share awards, number of treasury shares left of 1,336,000 is not enough to fulfil the 3rd tranche vesting in March 2022. Will Share Buyback be considered to replenish the treasury shareholdings?

Response: Pursuant to the Healthway Medical Performance Share Plan approved by the shareholders previously, the Company is authorised to issue new shares in settlement of share awards upon vesting. The Company does not have any immediate plans to adopt share buyback mandate. However, the

Board will seek shareholders' approval in the future should it deem necessary to adopt a share buyback mandate.

BY ORDER OF THE BOARD

Raymond Lam Kuo Wei Company Secretary

22 April 2021

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Gillian Goh, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.